NO961502L - Kombinasjon av progesteronantagonister og antiöstrogener med partiell, agonistisk virkning for anvendelse i hormonerstatningsterapi for kvinner under og etter klimakteriet - Google Patents

Kombinasjon av progesteronantagonister og antiöstrogener med partiell, agonistisk virkning for anvendelse i hormonerstatningsterapi for kvinner under og etter klimakteriet

Info

Publication number
NO961502L
NO961502L NO961502A NO961502A NO961502L NO 961502 L NO961502 L NO 961502L NO 961502 A NO961502 A NO 961502A NO 961502 A NO961502 A NO 961502A NO 961502 L NO961502 L NO 961502L
Authority
NO
Norway
Prior art keywords
pct
antiestrogens
menopause
combination
action
Prior art date
Application number
NO961502A
Other languages
English (en)
Other versions
NO961502D0 (no
NO308584B1 (no
Inventor
Kristof Chwalisz
Klaus Stockemann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO961502D0 publication Critical patent/NO961502D0/no
Publication of NO961502L publication Critical patent/NO961502L/no
Publication of NO308584B1 publication Critical patent/NO308584B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO961502A 1993-10-17 1996-04-16 Anvendelse av en kombinasjon av progesteronantagonister og antiøstrogener med partiell, agonistisk virkning for fremstilling av legemidler for hormonerstatningsterapi for kvinner under og etter klimakteriet NO308584B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4335876A DE4335876A1 (de) 1993-10-17 1993-10-17 Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
PCT/EP1994/003408 WO1995011013A2 (de) 1993-10-17 1994-10-17 Kombination von progesteronantagonisten und antiöstrogenen mit partialer agonistischer wirkung für die hormonsubstitutions-therapie für peri- und postmenopausale frauen

Publications (3)

Publication Number Publication Date
NO961502D0 NO961502D0 (no) 1996-04-16
NO961502L true NO961502L (no) 1996-06-14
NO308584B1 NO308584B1 (no) 2000-10-02

Family

ID=6500646

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961502A NO308584B1 (no) 1993-10-17 1996-04-16 Anvendelse av en kombinasjon av progesteronantagonister og antiøstrogener med partiell, agonistisk virkning for fremstilling av legemidler for hormonerstatningsterapi for kvinner under og etter klimakteriet

Country Status (19)

Country Link
US (1) US5719136A (no)
EP (1) EP0723439B1 (no)
JP (1) JPH09503774A (no)
KR (1) KR100348116B1 (no)
CN (1) CN1128613C (no)
AT (1) ATE196251T1 (no)
AU (1) AU691839B2 (no)
CA (1) CA2174327C (no)
CZ (1) CZ285690B6 (no)
DE (2) DE4335876A1 (no)
DK (1) DK0723439T3 (no)
ES (1) ES2150503T3 (no)
GR (1) GR3035054T3 (no)
HU (1) HUT74430A (no)
NO (1) NO308584B1 (no)
NZ (1) NZ274510A (no)
PT (1) PT723439E (no)
SK (1) SK281312B6 (no)
WO (1) WO1995011013A2 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE214269T1 (de) * 1997-06-27 2002-03-15 Akzo Nobel Nv Oral anzuwendende flüssige arzneilösung
CN1309637A (zh) * 1998-05-15 2001-08-22 美国家用产品公司 包含2－苯基－吲哚化合物和雌激素制剂的组合物
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
JP5005127B2 (ja) 1999-05-04 2012-08-22 ストラカン・インターナショナル・リミテッド アンドロゲングリコシド及びそのアンドロゲン作用活性
US6339098B1 (en) * 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CN1662234A (zh) * 2002-06-25 2005-08-31 惠氏公司 硫代－羟吲哚衍生物在治疗与激素有关的病症中的用途
EP1515680A4 (en) * 2002-06-25 2005-09-21 Wyeth Corp USE OF THIO-OXINDOLE DERIVATIVES IN THE TREATMENT OF SKIN DISORDERS
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
WO2004112724A2 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating hiv
US7247625B2 (en) * 2003-10-09 2007-07-24 Wyeth 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators
US7323455B2 (en) * 2004-03-24 2008-01-29 Wyeth 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
US7319152B2 (en) * 2005-09-19 2008-01-15 Wyeth 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
US20070066628A1 (en) * 2005-09-19 2007-03-22 Wyeth 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators
US7414142B2 (en) * 2005-09-19 2008-08-19 Wyeth 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators
MX2008014825A (es) * 2006-05-22 2008-12-01 Hormos Medical Ltd Moduladores selectivos del receptor de estrogeno o inhibidores de aromatasa para tratar prostatitis cronica no bacteriana.
TW200815428A (en) * 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
US20080045560A1 (en) * 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
US7649007B2 (en) * 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
US7618989B2 (en) * 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
WO2008021309A1 (en) * 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
US7538107B2 (en) 2006-08-15 2009-05-26 Wyeth Oxazinan-2-one derivatives useful as PR modulators
EP2821385B1 (en) * 2007-02-14 2016-07-27 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
CL2008000662A1 (es) * 2007-03-09 2008-04-25 Wyeth Corp Forma cristalina de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il) tiazo-4-il) benzonitrilo; metodo para la preparacion de dicho compuesto; composicion farmaceutica que comprende a dicho compuesto; kit farmaceutico que comprende a dicho compuesto; y su uso
US20080306131A1 (en) * 2007-06-05 2008-12-11 Wyeth Progesterone receptor modulator and uses thereof
EP2909164A1 (en) 2012-10-19 2015-08-26 Fermion Oy A process for the preparation of ospemifene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.

Also Published As

Publication number Publication date
KR960704535A (ko) 1996-10-09
CZ285690B6 (cs) 1999-10-13
NO961502D0 (no) 1996-04-16
ES2150503T3 (es) 2000-12-01
NO308584B1 (no) 2000-10-02
WO1995011013A3 (de) 1995-06-29
WO1995011013A2 (de) 1995-04-27
US5719136A (en) 1998-02-17
CN1128613C (zh) 2003-11-26
SK281312B6 (sk) 2001-02-12
DK0723439T3 (da) 2000-10-30
PT723439E (pt) 2001-01-31
SK48496A3 (en) 1997-01-08
EP0723439B1 (de) 2000-09-13
DE4335876A1 (de) 1995-04-20
KR100348116B1 (ko) 2002-11-25
DE59409522D1 (de) 2000-10-19
CA2174327C (en) 2007-05-22
CZ111196A3 (en) 1996-08-14
AU7856494A (en) 1995-05-08
AU691839B2 (en) 1998-05-28
NZ274510A (en) 2001-03-30
JPH09503774A (ja) 1997-04-15
HU9600992D0 (en) 1996-06-28
HUT74430A (en) 1996-12-30
ATE196251T1 (de) 2000-09-15
CA2174327A1 (en) 1995-04-27
GR3035054T3 (en) 2001-03-30
EP0723439A1 (de) 1996-07-31
CN1135176A (zh) 1996-11-06

Similar Documents

Publication Publication Date Title
NO961502L (no) Kombinasjon av progesteronantagonister og antiöstrogener med partiell, agonistisk virkning for anvendelse i hormonerstatningsterapi for kvinner under og etter klimakteriet
DE69527706T2 (de) Zusammensetzungen, die einen die mastzellendgranulation blockierenden h-1 rezeptorantagonisten als wirkstoff enthalten, für die behandlung von endogenen, schmerzhaften gastrointestinalen beschwerden nichtentzündlichen, nichtulzerativen ursprungs
Zajecka Strategies for the treatment of antidepressant-related sexual dysfunction
Pearson et al. Antiestrogen treatment of breast cancer: an overview
ES2107235T3 (es) Tableta de liberacion prolongada, revestida con pelicula, de astemizol y pseudoefedrina.
DE69734006D1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda-antagonist
Cohen et al. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder
FI963083A (fi) Normotensiivisen glaukooman hoito angiotensiini-II-antagonisteilla
CA2360313A1 (en) Glucocorticoid receptor modulators
KR100253111B1 (en) Pharmaceutical compositions of alkylsulphonamides 5ht1 agonists for rectal administration
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
Meuwissen et al. A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone
MXPA05012655A (es) Isomeros puros d-(17a)-13 -etil-17-hidroxi -18, 19-dinorpregn- 4-eno-20-ino -3-ona-3e -y ??3z- oxima, asi como el proceso para la sintesis de la mezcla de isomeros y los isomeros puros.
Goldman et al. Hyperprolactinemia with prolonged amenorrhea reversed with bromocriptine in a menopausal woman
Devi Antiestrogens
DK0701556T3 (da) N-((1-(4-(4-fluorphenoxy)butyl)-4-piperidinyl)N-methylamino)-2-benzo-thiazothiazololer som klasse III-antiarrytmiske midler